

---

**TORBET LABORATORIES IRELAND LIMITED**

---

**UNAUDITED**

**ABRIDGED FINANCIAL STATEMENTS**

**FOR THE YEAR ENDED 31 MARCH 2025**

---

**TORBET LABORATORIES IRELAND LIMITED**

---

**COMPANY INFORMATION**

---

**DIRECTORS** Yashvantrai Ondhia  
Punam Ondhia

**COMPANY SECRETARY** Yashvantrai Ondhia

**REGISTERED NUMBER** 637565

**REGISTERED OFFICE** 20 Holles Street  
Dublin 2

---

**TORBET LABORATORIES IRELAND LIMITED**

---

**CONTENTS**

---

	Page
<b>Directors' Responsibilities Statement</b>	1
<b>Abridged Statement of Financial Position</b>	2
<b>Statement of Changes in Equity</b>	3
<b>Notes to the Abridged Financial Statements</b>	4 - 7

---

**TORBET LABORATORIES IRELAND LIMITED**

---

**DIRECTORS' RESPONSIBILITIES STATEMENT  
FOR THE YEAR ENDED 31 MARCH 2025**

---

The Directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the Directors to prepare financial statements for each financial year. Under the law the directors have elected to prepare the financial statements in accordance with Companies Act 2014 and accounting standards issued by the Financial Reporting Council including FRS 102 "The Financial Reporting Standard applicable in the UK and Ireland", (Generally Accepted Accounting Practice in Ireland). Under the company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as to the financial year end and of the profit or loss of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the Directors are required to:

- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgments and estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business.


The Directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and directors' report comply with the Companies Act 2014 and enable the financial statements to be audited. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.


**DIRECTORS' DECLARATION ON UNAUDITED FINANCIAL STATEMENTS**

In relation to the financial statements as set out on pages 2 to 7:

- The Directors approve these financial statements and confirm that they are responsible for them, including selecting the appropriate accounting policies, applying them consistently and making, on a reasonable and prudent basis, the judgments underlying them. They have been prepared on the going concern basis on the grounds that the Company will continue in business.
- The Directors confirm that they have made available all the Company's accounting records and provided all the information necessary for the compilation of the financial statements.
- The Directors confirm that to the best of their knowledge and belief, the accounting records reflect all the transactions of the Company for the year ended 31 March 2025.

On behalf of the board

Signed by:  
  
A143640177F443D  
**Yashvantraai Ondhia**  
Director

Signed by:  
  
99BB74BBDDDF476...  
**Punam Ondhia**  
Director

Date:19-01-2026

---

**TORBET LABORATORIES IRELAND LIMITED**


---

**ABRIDGED STATEMENT OF FINANCIAL POSITION  
AS AT 31 MARCH 2025**


---


	Note	2025 €	2024 €
<b>CURRENT ASSETS</b>			
Debtors: amounts falling due within one year	4	250	23,272
Cash at bank and in hand		79,143	397,361
		<b>79,393</b>	420,633
Creditors: amounts falling due within one year	5	(8,422)	(283,211)
<b>NET CURRENT ASSETS</b>		<b>70,971</b>	137,422
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>		<b>70,971</b>	137,422
<b>NET ASSETS</b>		<b>70,971</b>	137,422
<b>CAPITAL AND RESERVES</b>			
Called up share capital presented as equity		1,000	1,000
Profit and loss account		69,971	136,422
<b>SHAREHOLDERS' FUNDS</b>		<b>70,971</b>	137,422

We, as Directors of Torbet Laboratories Ireland Limited, state that:

- (a) these financial statements have been prepared in accordance with the small companies regime.  
 (b) the Company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014.  
 (c) the Company is availing itself of the exemption on the grounds that the conditions specified in section 359 are satisfied.  
 (d) the members of the Company have not served a notice on the Company under section 334(1) in accordance with section 334(2).  
 (e) We acknowledge the Company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the state of the assets, liabilities and financial position of the Company at the end of its financial year and of its profit or loss for such a year and to otherwise comply with the provisions of Companies Act 2014 relating to financial statements so far as they are applicable to the Company.  
 (f) the Company has relied on the specific exemptions contained in section 352 of the Companies Act 2014; the Company has done so on the grounds that it is entitled to the benefit of that exemption as a small Company and the abridged financial statements have been properly prepared in accordance with section 353 of the Companies Act 2014.

The financial statements were approved and authorised for issue by the board:

Signed by:  
  
 A143640177F443D  
**Yashvantraï Ondhia**  
 Director

Signed by:  
  
 99BB74BB00DF476...  
**Punam Ondhia**  
 Director

Date: 19-01-2026

---

**TORBET LABORATORIES IRELAND LIMITED**


---

**STATEMENT OF CHANGES IN EQUITY  
FOR THE YEAR ENDED 31 MARCH 2025**


---

	Called up share capital	Profit and loss account	Total equity
	€	€	€
<b>At 1 April 2023</b>	<b>1,000</b>	<b>245,504</b>	<b>246,504</b>
<b>COMPREHENSIVE INCOME FOR THE YEAR</b>			
Loss for the period	-	(109,082)	(109,082)
<b>At 1 April 2024</b>	<b>1,000</b>	<b>136,422</b>	<b>137,422</b>
<b>COMPREHENSIVE INCOME FOR THE YEAR</b>			
Loss for the year	-	(66,451)	(66,451)
<b>AT 31 MARCH 2025</b>	<b>1,000</b>	<b>69,971</b>	<b>70,971</b>

The notes on pages 4 to 7 form part of these financial statements.

---

**TORBET LABORATORIES IRELAND LIMITED**

---

**NOTES TO THE ABRIDGED FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2025**

---

**1. GENERAL INFORMATION**

Torbet Laboratories Ireland Limited ("the Company") is a private company limited by shares. The company's registered office is 20 Holles Street, Dublin 2 and its registered number is 637565. The company is a limited liability company incorporated in Ireland and tax resident in the United Kingdom.

The significant accounting policies adopted by the Company and applied consistently in the preparation of these financial statements are as follows:

**2. ACCOUNTING POLICIES****2.1 BASIS OF PREPARATION OF FINANCIAL STATEMENTS**

The Financial Statements are prepared on the going concern basis, under the historical cost convention, and comply with the financial reporting standards of the Financial Reporting Council including FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" ("FRS 102") as adapted by Section 1A of FRS 102 and the Companies Act 2014.

**2.2 FOREIGN CURRENCY TRANSLATION****Functional and presentation currency**

The Company's functional and presentational currency is Euros.

**Transactions and balances**

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss except when deferred in other comprehensive income as qualifying cash flow hedges.

Foreign exchange gains and losses that relate to borrowings and cash and cash equivalents are presented in the Statement of Comprehensive Income within 'finance income or costs'. All other foreign exchange gains and losses are presented in profit or loss within 'other operating income'.

---

**TORBET LABORATORIES IRELAND LIMITED**

---

**NOTES TO THE ABRIDGED FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2025**

---

**2. ACCOUNTING POLICIES (CONTINUED)****2.3 REVENUE**

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

**Sale of goods**

Revenue from the sale of goods is recognised when all of the following conditions are satisfied:

- the Company has transferred the significant risks and rewards of ownership to the buyer;
- the Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
- the amount of revenue can be measured reliably;
- it is probable that the Company will receive the consideration due under the transaction; and
- the costs incurred or to be incurred in respect of the transaction can be measured reliably.

**2.4 TAXATION**

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the Company operates and generates income.

**2.5 DEBTORS**

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

**2.6 CASH AND CASH EQUIVALENTS**

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

**2.7 CREDITORS**

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

---

**TORBET LABORATORIES IRELAND LIMITED**


---

**NOTES TO THE ABRIDGED FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2025**


---

**2. ACCOUNTING POLICIES (CONTINUED)****2.8 SHARE CAPITAL**

Ordinary shares are classed as equity.

**2.9 CASH FLOW STATEMENT EXEMPTION**

The company has availed of the exemption contained in Section 1A of FRS 102 and as a result have elected not to prepare a cash flow statement.

**3. EMPLOYEES**

The Company has no employees other than the Directors, who did not receive any remuneration (2024 - €NIL).

**4. DEBTORS**

	<b>2025</b>	2024
	€	€
Amounts owed by associated undertakings	-	23,000
Other debtors	<b>250</b>	272
	<b>250</b>	23,272
	<u><b>250</b></u>	<u>23,272</u>

**5. CREDITORS: Amounts falling due within one year**

	<b>2025</b>	2024
	€	€
Amounts owed to group undertakings	<b>3,789</b>	250,098
Amounts owed to associated undertakings	-	30,000
Accruals	<b>4,633</b>	3,113
	<b>8,422</b>	283,211
	<u><b>8,422</b></u>	<u>283,211</u>

**6. TRANSACTIONS WITH DIRECTORS****Yashvantrai Ondhia**

Yashvantrai Ondhia is a director and shareholder of Torbet Laboratories Ireland Limited. At 1 April 2024 and 31 March 2025, Yashvantrai Ondhia owed €150 to Torbet Laboratories Ireland Limited.

**Punam Ondhia**

Punam Ondhia is a director and shareholder of Torbet Laboratories Ireland Limited. At 1 April 2024 and 31 March 2025, Punam Ondhia owed €100 to Torbet Laboratories Ireland Limited.

---

**TORBET LABORATORIES IRELAND LIMITED**

---

**NOTES TO THE ABRIDGED FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 MARCH 2025**

---

**7. RELATED PARTY TRANSACTIONS**

The key management of the company comprises the directors. The directors did not receive any remuneration during the year.

**Torbet Laboratories Limited**

Torbet Laboratories Limited owns 75% of the issued share capital of Torbet Laboratories Ireland Limited. At 1 April 2024, Torbet Laboratories Ireland Limited owed €250,098 to Torbet Laboratories Limited. During the year, Torbet Laboratories Ireland Limited repaid €246,309 to Torbet Laboratories Limited. At 31 March 2025, Torbet Laboratories Ireland Limited owed €3,789 to Torbet Laboratories Limited.

**Cambridge Healthcare Ireland Limited**

Yashvantrai Ondhia and Punam Ondhia are directors of Cambridge Healthcare Ireland Limited. At 1 April 2024, Cambridge Healthcare Ireland Limited owed €23,000 to Torbet Laboratories Ireland Limited. During the year, Cambridge Healthcare Ireland Limited repaid €23,000 to Torbet Laboratories Ireland Limited. At 31 March 2025, there is no balance due from Cambridge Healthcare Ireland Limited.

**Cambridge Healthcare Supplies Limited**

Yashvantrai Ondhia and Punam Ondhia are directors of Cambridge Healthcare Supplies Limited. At 1 April 2024, Torbet Laboratories Ireland Limited owed €30,000 to Cambridge Healthcare Supplies Limited. During the year, Torbet Laboratories Ireland Limited repaid €30,000 to Cambridge Healthcare Supplies Limited. At 31 March 2025, there is no balance due to Cambridge Healthcare Supplies Limited.

**8. CONTROLLING PARTY**

Torbet Laboratories Limited, an entity registered in the United Kingdom, holds 75% of the issued share capital of Torbet Laboratories Ireland Limited. Torbet Laboratories Limited is controlled by Yashvantrai Ondhia who owns 70% of the issued share capital of Torbet Laboratories Limited.

**9. APPROVAL OF FINANCIAL STATEMENTS**

The board of Directors approved these financial statements for issue on 19-01-2026